Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
07:00am, Thursday, 01'st Feb 2024
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11 posters across its development programs will be included at the
Time to buy these 3 healthcare companies that raised revenue guidance?
09:00am, Tuesday, 16'th Jan 2024
The new year brings a clean slate heading into the fourth-quarter earnings season. Companies can usually gauge if their previous forecasts were in line or need to be adjusted to warn or prepare invest
Amicus (FOLD) Issues Preliminary Revenue Results for FY23
11:23am, Monday, 08'th Jan 2024
Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
11:16am, Friday, 29'th Dec 2023
Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential.
Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated
02:17pm, Thursday, 09'th Nov 2023
Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates.
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
07:00am, Wednesday, 01'st Nov 2023
PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i
Amicus Therapeutics: The Right Play Now
12:24pm, Tuesday, 31'st Oct 2023
Amicus Therapeutics, Inc. is a commercial-stage biotech company focused on developing therapies for rare diseases. The company recently received FDA approval for its combination therapy Pombiliti + Op
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
07:00am, Friday, 27'th Oct 2023
PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023
Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug
10:31am, Friday, 29'th Sep 2023
Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.
3 Stocks Worth a Watch for Solid Earnings Acceleration
08:16am, Wednesday, 20'th Sep 2023
Some of the notable companies to have witnessed solid earnings acceleration as of now are Amicus Therapeutics (FOLD), Genius Sports (GENI) and Viad (VVI).
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
07:00am, Friday, 01'st Sep 2023
PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in
FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss
01:42pm, Wednesday, 09'th Aug 2023
FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.
Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance
10:42am, Wednesday, 09'th Aug 2023
Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.
Amicus Therapeutics Inc. (FOLD) Q2 2023 Earnings Call Transcript
03:29pm, Tuesday, 08'th Aug 2023
Amicus Therapeutics Inc. (NASDAQ:FOLD ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President
Why Earnings Season Could Be Great for Amicus Therapeutics (FOLD)
09:53am, Monday, 07'th Aug 2023
Amicus Therapeutics (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
